ACAD vs NBIX
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in developing and commercializing innovative treatments for central nervous system and rare disease indications. NBIX: A neuroscience-focused biopharmaceutical company commercializing specialized treatments for neurological and endocrine disorders while advancing a diverse pipeline of therapeutic modalities.
Side-by-side fundamentals
| Metric | ACAD | NBIX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $19.58 | $141.25 | |
| Market cap | $3.4B | $14.4B | |
| P/E as of 2026-10-08 | 8.85 | 20.71 | ACAD lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 0.47 | |
| Net margin FY2025, SEC XBRL | +36.5% | +16.7% | ACAD higher |
| Gross margin FY2025, SEC XBRL | +91.7% | n/a | |
| Operating margin FY2025, SEC XBRL | +9.8% | +21.6% | NBIX higher |
| ROE FY2025, SEC XBRL | +31.9% | +14.7% | ACAD higher |
| ROA FY2025, SEC XBRL | +25.0% | +10.3% | ACAD higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-09-03 | +47.0% | +34.4% | ACAD higher |
| Revenue CAGR (3y) SEC XBRL | +27.5% | +24.3% | ACAD higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.85 | 0.78 | |
| 1-year return as of 2026-10-08 close | -8.1% | +1.6% | NBIX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.